Protembis Successfully Closes $ 10 Million Series A Financing
Protembis Develops a Novel Catheter-Based Filter System to Protect Patients Undergoing Interventional Heart Procedures from Stroke and Other Neurological Injuries
The Managing Directors and founders of Protembis GmbH, Karl von Mangoldt and Conrad Rasmus, have successfully closed a Series A financing round in a structured process.
A syndicate consisting of the US listed medical technology company Abiomed Inc., the Seed Fonds III for the region of Aachen and Mönchengladbach GmbH & Co. KG, coparion GmbH & Co. KG, as well as renowned family offices and internationally experienced angel investors, has invested in the Aachen-based medical technology startup Protembis GmbH. The company is developing a novel and innovative cerebral protection system that is designed to minimize the risk of stroke and other neurological injury, particularly during catheter-based heart valve implantations. Protembis has raised a total of $ 10 million in an oversubscribed Series A financing round and expects to bring its product to market maturity with this round.